broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K81473043-001-19-5 | ACH-000903 | FTC133_THYROID | MTS010 | 1 | 0.426729 | 1.379405 | 0.487438 | 0.77449 | 0.013783 | 0.055462 | tanespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 3 | true | ACH-000903 |
BRD-K82135108-001-04-3 | ACH-000903 | FTC133_THYROID | MTS010 | 1 | 1.758446 | 0.266645 | 0.16632 | 1 | 0.066393 | null | elesclomol | oxidative stress inducer | HSPA1A | null | null | CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1 | Phase 3 | true | ACH-000903 |
BRD-K82746043-001-19-3 | ACH-000903 | FTC133_THYROID | MTS010 | 1 | 0.275441 | 0.706523 | 0.638717 | 0.491986 | 0.00923 | 0.028658 | navitoclax | BCL inhibitor | BCL2, BCL2L1, BCL2L2 | null | null | CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 | Phase 2 | true | ACH-000903 |
BRD-K82818427-001-04-8 | ACH-000903 | FTC133_THYROID | MTS010 | 1 | 0.579208 | 1.578901 | 0.326514 | 0.849699 | 0.31313 | null | batimastat | matrix metalloprotease inhibitor | ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8 | null | null | CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO | Phase 3 | true | ACH-000903 |
BRD-K83029223-001-01-3 | ACH-000903 | FTC133_THYROID | MTS010 | 1 | 0.751908 | 0.168084 | -0.24704 | 0.863604 | 0.001393 | null | litronesib | kinesin-like spindle protein inhibitor | KIF11 | null | null | CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 | Phase 2 | true | ACH-000903 |
BRD-K83988098-001-02-0 | ACH-000903 | FTC133_THYROID | MTS010 | 1 | 0.592098 | 2.213833 | 0.347383 | 0.7826 | 0.000885 | null | alvespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 2 | true | ACH-000903 |
BRD-K85402309-043-01-9 | ACH-000903 | FTC133_THYROID | MTS010 | 1 | 1.029703 | -0.486072 | -0.018329 | 1 | 3.5533 | null | dovitinib | EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB | null | null | CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O | Phase 3 | true | ACH-000903 |
BRD-K85606544-001-09-1 | ACH-000903 | FTC133_THYROID | MTS010 | 1 | 0.891631 | -4.033914 | 0.083329 | 0.914689 | 1.26843 | null | neratinib | EGFR inhibitor | EGFR, ERBB2, KDR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 3 | true | ACH-000903 |
BRD-K86118762-001-01-8 | ACH-000903 | FTC133_THYROID | MTS010 | 1 | 1.266686 | 0.731933 | 0.179266 | 1 | 0.237525 | null | linsitinib | IGF-1 inhibitor | IGF1R, INSR, INSRR | null | null | C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 | Phase 3 | true | ACH-000903 |
BRD-K86972824-001-01-4 | ACH-000903 | FTC133_THYROID | MTS010 | 1 | 0.789518 | -0.177436 | 0.021466 | 0.89735 | 0.05818 | null | oltipraz | nuclear factor erythroid derived, like (NRF2) activator | ANG | null | null | Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1 | Phase 3 | true | ACH-000903 |
BRD-K87737963-001-06-0 | ACH-000903 | FTC133_THYROID | MTS010 | 1 | 1.054232 | -0.009175 | -0.006603 | 1 | 1.181831 | null | cyt387 | null | JAK1, JAK2, JAK3 | null | null | O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1 | Phase 3 | true | ACH-000903 |
BRD-K87782578-001-01-4 | ACH-000903 | FTC133_THYROID | MTS010 | 1 | 0.878349 | -0.630534 | -0.065265 | 0.933457 | 0.128987 | null | AVL-292 | Bruton's tyrosine kinase (BTK) inhibitor | BTK, YES1 | null | null | COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1 | Phase 2 | true | ACH-000903 |
BRD-K87909389-003-03-4 | ACH-000903 | FTC133_THYROID | MTS010 | 1 | 0.243681 | 0.661143 | 0.50493 | 0.725408 | 0.335702 | 0.922301 | alvocidib | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM | null | null | CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000903 |
BRD-K88510285-001-17-8 | ACH-000903 | FTC133_THYROID | MTS010 | 1 | 0.213846 | 5.305793 | -0.198706 | 0.630902 | 0.026292 | 0.029209 | bortezomib | NFkB pathway inhibitor, proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA | hematologic malignancy | multiple myeloma, mantle cell lymphoma (MCL) | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O | Launched | true | ACH-000903 |
BRD-K89014967-001-04-3 | ACH-000903 | FTC133_THYROID | MTS010 | 1 | 1.093097 | 0.366414 | 0.002251 | 1 | 0.0407 | null | AS-703026 | MEK inhibitor | MAP2K1, MAP2K2 | null | null | OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F | Phase 2 | true | ACH-000903 |
BRD-K92441787-001-04-1 | ACH-000903 | FTC133_THYROID | MTS010 | 1 | 0.759926 | -3.110076 | 0.225233 | 0.843332 | 0.343368 | null | bexarotene | retinoid receptor agonist | RXRA, RXRB, RXRG | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C | Launched | true | ACH-000903 |
BRD-K92723993-001-17-4 | ACH-000903 | FTC133_THYROID | MTS010 | 1 | 1.008621 | -0.017144 | -0.020064 | 1 | 0.005623 | null | imatinib | Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET | hematologic malignancy, oncology | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST) | CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1 | Launched | true | ACH-000903 |
BRD-K95142244-001-01-5 | ACH-000903 | FTC133_THYROID | MTS010 | 1 | 0.745483 | 0.40254 | 0.029927 | 0.86002 | 0.040896 | null | talazoparib | PARP inhibitor | PARP2 | null | null | Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1 | Phase 3 | true | ACH-000903 |
BRD-K96123349-236-02-8 | ACH-000903 | FTC133_THYROID | MTS010 | 1 | 0.789413 | 5.582106 | 0.263413 | 0.95503 | 1.258858 | null | brequinar | dihydroorotate dehydrogenase inhibitor | DHODH | null | null | Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F | Phase 2 | true | ACH-000903 |
BRD-K98572433-001-02-9 | ACH-000903 | FTC133_THYROID | MTS010 | 1 | 1.65257 | 0.748526 | 0.42064 | 1 | 0.62898 | null | AZD8931 | EGFR inhibitor | EGFR, ERBB2, ERBB3 | null | null | CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC | Phase 2 | true | ACH-000903 |
BRD-K99113996-001-02-0 | ACH-000903 | FTC133_THYROID | MTS010 | 1 | 1.187368 | -0.11182 | -0.034699 | 1 | 3,885.092971 | null | AZD2014 | mTOR inhibitor | MTOR | null | null | CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C | Phase 2 | true | ACH-000903 |
BRD-K99749624-001-07-0 | ACH-000903 | FTC133_THYROID | MTS010 | 1 | 1.408456 | 0.153826 | 0.024694 | 1 | 1.981333 | null | linifanib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK | null | null | Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1 | Phase 3 | true | ACH-000903 |
BRD-M97302542-001-04-4 | ACH-000903 | FTC133_THYROID | MTS010 | 1 | 1.135328 | -0.853572 | 0.191607 | 1 | 0.147406 | null | dichloroacetate | pyruvate dehydrogenase kinase inhibitor | PDK1 | null | null | [Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl | Phase 3 | true | ACH-000903 |
BRD-A25234499-001-19-1 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.826984 | 4.438779 | 0.050027 | 0.920452 | 0.115404 | null | aminoglutethimide | glucocorticoid receptor antagonist | CYP11A1, CYP19A1 | endocrinology, oncology | Cushing's syndrome, breast cancer | CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1 | Launched | true | ACH-000905 |
BRD-A70858459-001-01-7 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.474105 | 0.105979 | 0.058757 | 0.743253 | 0.123087 | null | estramustine | DNA alkylating agent | ESR1, ESR2, MAP1A, MAP2 | oncology | prostate cancer | C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O | Launched | true | ACH-000905 |
BRD-A74914197-001-02-9 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.296626 | 6.133787 | 0.70585 | 0.564617 | 0.001538 | 0.001781 | pralatrexate | dihydrofolate reductase inhibitor | DHFR, TYMS | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 | Launched | true | ACH-000905 |
BRD-K02113016-001-19-6 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.537892 | 0.708171 | 0.214688 | 0.844387 | 0.434595 | null | olaparib | PARP inhibitor | PARP1, PARP2 | oncology | ovarian cancer | Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1 | Launched | true | ACH-000905 |
BRD-K02130563-001-11-4 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.07307 | 0.452433 | 0.82283 | 0.367416 | 0.00793 | 0.011244 | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-000905 |
BRD-K03390685-001-01-7 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.43682 | 0.737578 | 0.473272 | 0.77967 | 0.240132 | 3.967125 | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-000905 |
BRD-K03406345-001-21-1 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.690349 | 0.487382 | 0.076013 | 0.87432 | 0.237331 | null | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000905 |
BRD-K03449891-001-08-6 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.083391 | 6.274118 | 0.656505 | 0.745921 | 0.678759 | 0.698789 | foretinib | VEGFR inhibitor | FLT1, FLT4, KDR, MET | null | null | COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1 | Phase 2 | true | ACH-000905 |
BRD-K03765900-001-01-9 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | -0.141803 | 0.505195 | 0.54413 | 0.665748 | 0.939027 | 0.572856 | XL-647 | EGFR inhibitor, VEGFR inhibitor | EGFR, EPHB4, ERBB2, FLT4, KDR | null | null | COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1 | Phase 3 | true | ACH-000905 |
BRD-K05804044-001-18-5 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.276337 | 2.213081 | 0.536506 | 0.758892 | 0.394388 | 0.567272 | AZ-628 | RAF inhibitor | BRAF, RAF1 | null | null | Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1 | Preclinical | true | ACH-000905 |
BRD-K06814349-304-02-7 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.281797 | 3.543124 | 0.381443 | 0.788783 | 0.576115 | 0.728029 | fosbretabulin | tubulin polymerization inhibitor, VE-cadherin antagonist | CDH5 | null | null | COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O | Phase 3 | true | ACH-000905 |
BRD-K08109215-001-06-4 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.607823 | 3.789862 | 0.339417 | 0.955464 | 3.335459 | null | I-BET-762 | bromodomain inhibitor | BRD2, BRD3, BRD4 | null | null | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 | Phase 2 | true | ACH-000905 |
BRD-K08542803-001-02-3 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | -0.284935 | 0.345423 | 0.757765 | 0.533015 | 0.563197 | 0.152628 | gambogic-acid | caspase activator | BCL2 | null | null | CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C | Phase 2 | true | ACH-000905 |
BRD-K08547377-001-04-4 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.22434 | 3.459843 | 0.829842 | 0.487086 | 0.016331 | 0.019397 | irinotecan | topoisomerase inhibitor | TOP1, TOP1MT | oncology | colorectal cancer | CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12 | Launched | true | ACH-000905 |
BRD-K08703257-001-13-9 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.905548 | -3.580927 | 0.006124 | 0.934118 | 0.531043 | null | 3-amino-benzamide | PARP inhibitor | PARP1 | null | null | NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1 | Phase 2 | true | ACH-000905 |
BRD-K08799216-001-05-3 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.253334 | 1.257437 | 0.819549 | 0.657527 | 0.116862 | 0.20498 | pelitinib | EGFR inhibitor | EGFR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 2 | true | ACH-000905 |
BRD-K09951645-001-11-8 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.543016 | 0.784677 | 0.213478 | 0.752963 | 0.051728 | null | dabrafenib | RAF inhibitor | BRAF, LIMK1, NEK11, RAF1, SIK1 | oncology | melanoma | CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F | Launched | true | ACH-000905 |
BRD-K11267252-001-05-1 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 1.352139 | -0.324741 | 0.058011 | 1 | 0.002748 | null | alectinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1 | Launched | true | ACH-000905 |
BRD-K11630072-001-13-2 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.283668 | 0.144443 | 0.1487 | 0.595041 | 0.011766 | 3.886941 | carmofur | thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O | Launched | true | ACH-000905 |
BRD-K12184916-001-19-6 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.511019 | 1.825032 | 0.407655 | 0.622033 | 0.005325 | null | NVP-BEZ235 | mTOR inhibitor, PI3K inhibitor | ATR, MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1 | Phase 2 | true | ACH-000905 |
BRD-K12343256-001-14-7 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.075565 | 0.568592 | 0.634603 | 0.520011 | 0.063191 | 0.084296 | trametinib | MEK inhibitor | MAP2K1, MAP2K2 | oncology | melanoma | CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O | Launched | true | ACH-000905 |
BRD-K13049116-001-04-0 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | -0.230671 | 0.303239 | 0.433882 | 0.531743 | 0.51273 | 0.146749 | BMS-754807 | IGF-1 inhibitor | AKT1, IGF1R | null | null | C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1 | Phase 2 | true | ACH-000905 |
BRD-K13390322-001-06-3 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | -0.019342 | 0.652525 | 0.528533 | 0.643623 | 0.391371 | 0.369256 | AT-7519 | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK9 | null | null | Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1 | Phase 2 | true | ACH-000905 |
BRD-K13514097-001-04-6 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.733596 | -0.050968 | -0.035301 | 0.87904 | 0.002061 | null | everolimus | mTOR inhibitor | MTOR | oncology, neurology/psychiatry, genetics, urology | breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO | Launched | true | ACH-000905 |
BRD-K13662825-001-07-5 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | -0.026654 | 0.374181 | 0.398702 | 0.408906 | 0.007005 | 0.006097 | dinaciclib | CDK inhibitor | CDK1, CDK2, CDK5, CDK9 | null | null | CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO | Phase 3 | true | ACH-000905 |
BRD-K14109347-001-03-4 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.131061 | 6.539752 | 0.558655 | 0.78175 | 0.873788 | 0.915363 | LY2603618 | CHK inhibitor | CHEK1 | null | null | Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1 | Phase 2 | true | ACH-000905 |
BRD-K15179879-001-03-2 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.20633 | 5.969035 | 0.842925 | 0.512425 | 0.025752 | 0.028153 | carfilzomib | proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9 | hematologic malignancy | multiple myeloma | CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 | Launched | true | ACH-000905 |
BRD-K15600710-066-05-8 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.132771 | 8.930255 | 0.65991 | 0.713012 | 0.395647 | 0.409559 | obatoclax | BCL inhibitor | BCL2 | null | null | COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 | Phase 3 | true | ACH-000905 |
BRD-K17555800-003-02-3 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.527456 | 0.210266 | -0.259813 | 0.733118 | 0.020363 | null | talmapimod | p38 MAPK inhibitor | MAPK11, MAPK14 | null | null | C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C | Phase 2 | true | ACH-000905 |
BRD-K17610631-001-03-3 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.3459 | 0.538227 | 0.196195 | 0.74085 | 0.245496 | 2.186608 | indisulam | CDK inhibitor | CA1, CA12, CA14, CA2, CA6, CA7, CA9 | null | null | NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12 | Phase 2 | true | ACH-000905 |
BRD-K17743125-001-08-4 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.076324 | 1.017618 | 0.723997 | 0.702143 | 0.455421 | 0.535925 | belinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1 | Launched | true | ACH-000905 |
BRD-K17894950-001-14-3 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 1.399605 | -0.206005 | 0.005423 | 1 | 0.001666 | null | indirubin | CDK inhibitor, glycogen synthase kinase inhibitor | CDK1, CDK5, GSK3A | null | null | O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O | Phase 2/Phase 3 | true | ACH-000905 |
BRD-K18961567-001-01-1 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.197712 | 0.758292 | 0.363087 | 0.67249 | 0.200083 | 0.388527 | LY2801653 | MET inhibitor | MET | null | null | Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1 | Phase 2 | true | ACH-000905 |
BRD-K19540840-001-09-4 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.149641 | 1.522573 | 0.649486 | 0.794614 | 0.977664 | 1.234905 | saracatinib | src inhibitor | ABL1, LCK, SRC, YES1 | null | null | CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1 | Phase 2/Phase 3 | true | ACH-000905 |
BRD-K19687926-001-04-1 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.436133 | 1.426856 | 0.452837 | 0.72884 | 0.094048 | 0.397821 | lapatinib | EGFR inhibitor | EGFR, ERBB2 | oncology | breast cancer | CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1 | Launched | true | ACH-000905 |
BRD-K19796430-001-05-6 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.717497 | 1.213661 | 0.042174 | 0.769916 | 0.003347 | null | sonidegib | smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1 | Launched | true | ACH-000905 |
BRD-K22064724-001-01-8 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.099437 | 1.863373 | 0.691798 | 0.600416 | 0.134895 | 0.151941 | napabucasin | STAT inhibitor | STAT3 | null | null | CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O | Phase 3 | true | ACH-000905 |
BRD-K22822991-001-02-3 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 26.71637 | 0.146582 | -0.013544 | 1 | 10,016,296,540,889,638,000,000,000,000,000,000,000,000,000 | null | odanacatib | cathepsin inhibitor | CTSK | null | null | CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N | Phase 3 | true | ACH-000905 |
BRD-K23228615-001-02-8 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.186171 | 5.165796 | 0.534181 | 0.859886 | 1.881016 | 2.058492 | GDC-0980 | mTOR inhibitor, PI3K inhibitor | FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK | null | null | C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1 | Phase 2 | true | ACH-000905 |
BRD-K23984367-001-07-5 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.814448 | 0.100503 | -0.006562 | 0.891709 | 0.002542 | null | sorafenib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET | oncology | renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1 | Launched | true | ACH-000905 |
BRD-K26026438-001-01-0 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.399343 | 0.490054 | 0.511981 | 0.731666 | 0.145786 | 3.839037 | tucatinib | EGFR inhibitor | ERBB2 | null | null | Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 | Phase 2 | true | ACH-000905 |
BRD-K26657438-001-15-2 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.824445 | -0.082998 | -0.106767 | 0.883294 | 332.470188 | null | imiquimod | interferon inducer, toll-like receptor agonist | TLR7, TLR8 | dermatology, infectious disease, oncology | actinic keratosis (AK), genital warts, basal cell carcinoma (BCC) | CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12 | Launched | true | ACH-000905 |
BRD-K28822270-001-03-7 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.03753 | 1.653584 | 0.647874 | 0.738322 | 0.753808 | 0.79023 | resminostat | HDAC inhibitor | HDAC1, HDAC3, HDAC6, HDAC8 | null | null | CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO | Phase 2 | true | ACH-000905 |
BRD-K29905972-001-06-3 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.123791 | 0.705405 | 0.469407 | 0.765234 | 0.941435 | 1.409024 | axitinib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, FLT1, FLT4, KDR, PLK4 | oncology | renal cell carcinoma (RCC) | CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1 | Launched | true | ACH-000905 |
BRD-K30577245-001-05-0 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.082494 | 0.496308 | 0.660838 | 0.329903 | 0.000292 | 0.00042 | docetaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1 | oncology | breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC) | CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C | Launched | true | ACH-000905 |
BRD-K31698212-001-02-9 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.712536 | 0.866216 | 0.178448 | 0.921104 | 0.784698 | null | icotinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1 | Launched | true | ACH-000905 |
BRD-K31928526-001-02-1 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.117371 | 2.184138 | 0.726111 | 0.641673 | 0.194526 | 0.219877 | barasertib | Aurora kinase inhibitor | AURKA, AURKB | null | null | CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O | Phase 2/Phase 3 | true | ACH-000905 |
BRD-K33379087-001-07-5 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.53856 | 0.198294 | 0.024363 | 0.643184 | 0.000106 | null | tivantinib | tyrosine kinase inhibitor | MET | null | null | O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23 | Phase 3 | true | ACH-000905 |
BRD-K33610132-001-02-9 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.322266 | 4.206766 | 0.380796 | 0.923309 | 3.34272 | 4.274475 | rociletinib | EGFR inhibitor | EGFR | null | null | COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O | Phase 3 | true | ACH-000905 |
BRD-K33622447-066-01-9 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 1.170791 | -1.695472 | 0.054482 | 1 | 0.055886 | null | abemaciclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1 | Launched | true | ACH-000905 |
BRD-K35520305-001-16-9 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.64074 | -0.041902 | -0.06066 | 0.804123 | 6.013616 | null | dacarbazine | DNA alkylating agent | PGD, POLA2 | oncology, hematologic malignancy | melanoma, Hodgkin's lymphoma | CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O | Launched | true | ACH-000905 |
BRD-K36627727-001-05-4 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.360188 | 0.243394 | 0.213879 | 0.630947 | 0.018957 | 3.560873 | tamibarotene | retinoid receptor agonist | RARA, RARB | hematologic malignancy | acute promyelocytic leukemia (APL) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12 | Launched | true | ACH-000905 |
BRD-K36788280-001-01-2 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.656442 | -1.276197 | 0.13136 | 0.946872 | 0.002415 | null | ribociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1 | Launched | true | ACH-000905 |
BRD-K37379014-001-02-0 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | -0.044395 | 0.895428 | 0.399585 | 0.717167 | 0.012571 | 0.011432 | filanesib | kinesin inhibitor, kinesin-like spindle protein inhibitor | KIF11 | null | null | CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F | Phase 3 | true | ACH-000905 |
BRD-K38332599-001-01-3 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.248984 | 1.735075 | 0.815525 | 0.72669 | 0.292911 | 0.43573 | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-000905 |
BRD-K38527262-300-01-0 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.543887 | 0.395675 | 0.172313 | 0.769858 | 0.067759 | null | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-000905 |
BRD-K38852836-001-02-1 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.118356 | 1.155966 | 0.568553 | 0.444117 | 0.005442 | 0.006875 | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-000905 |
BRD-K39974922-001-04-3 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.724456 | 1.15849 | 0.185044 | 0.900323 | 0.303079 | null | lenvatinib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT4, KDR | oncology | thyroid cancer | COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O | Launched | true | ACH-000905 |
BRD-K41859756-001-06-8 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.088283 | 2.977994 | 0.793952 | 0.416189 | 0.005012 | 0.00535 | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-000905 |
BRD-K42495768-001-01-7 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.906276 | -0.0076 | -0.076604 | 0.952845 | 0.405454 | null | tasisulam | apoptosis stimulant | null | null | null | Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1 | Phase 3 | true | ACH-000905 |
BRD-K42805893-001-04-9 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.164529 | 0.949259 | 0.499599 | 0.813648 | 1.325213 | 2.017748 | osimertinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12 | Launched | true | ACH-000905 |
BRD-K42828737-001-03-3 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.431134 | 5.314014 | 0.258209 | 0.892858 | 1.607698 | 2.334623 | sunitinib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET | oncology | gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET) | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C | Launched | true | ACH-000905 |
BRD-K42898655-001-01-8 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.597456 | 14.875078 | 0.310468 | 0.791312 | 0.004081 | null | temsirolimus | mTOR inhibitor | MTOR | oncology | renal cell carcinoma (RCC) | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO | Launched | true | ACH-000905 |
BRD-K43389675-001-02-1 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.056243 | 0.715648 | 0.441922 | 0.474368 | 0.04333 | 0.051192 | daunorubicin | RNA synthesis inhibitor, topoisomerase inhibitor | TOP2A, TOP2B | hematologic malignancy | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O | Launched | true | ACH-000905 |
BRD-K44227013-001-06-4 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.111369 | 4.503895 | 0.625886 | 0.758243 | 0.713468 | 0.754522 | ponatinib | Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1 | Launched | true | ACH-000905 |
BRD-K44408410-001-17-6 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.041694 | 2.926941 | 0.594325 | 0.867094 | 2.620531 | 2.699665 | 2-methoxyestradiol | hypoxia inducible factor inhibitor | COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB | null | null | COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O | Phase 2 | true | ACH-000905 |
BRD-K44827188-001-06-0 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.844117 | 0.059734 | -0.002815 | 0.937398 | 64.903689 | null | vismodegib | hedgehog pathway inhibitor, smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O | Launched | true | ACH-000905 |
BRD-K46386702-001-02-1 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.42116 | 0.091959 | -0.017603 | 0.671346 | 0.003829 | null | ARRY-334543 | EGFR inhibitor | ERBB2 | null | null | C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 | Phase 2 | true | ACH-000905 |
BRD-K49328571-001-15-0 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.117513 | 0.598355 | 0.581147 | 0.331781 | 0.004116 | 0.006441 | dasatinib | Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor | ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1 | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1 | Launched | true | ACH-000905 |
BRD-K49350383-001-14-5 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.699951 | 5.242614 | -0.046676 | 0.86452 | 0.125016 | null | thioguanine | purine antagonist | IMPDH1, IMPDH2 | hematologic malignancy | acute myeloid leukemia (AML) | Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1 | Launched | true | ACH-000905 |
BRD-K50010139-001-01-5 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.077051 | 0.119791 | 0.147385 | 0.496249 | 0.016141 | 0.065263 | poziotinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C | Phase 2 | true | ACH-000905 |
BRD-K50168500-001-07-9 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | -0.031025 | 0.713344 | 0.671399 | 0.80326 | 2.412695 | 2.217427 | canertinib | EGFR inhibitor | AKT1, EGFR, ERBB2, ERBB4 | null | null | Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl | Phase 3 | true | ACH-000905 |
BRD-K51313569-001-07-8 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 1.073307 | -0.012697 | -0.045739 | 1 | 1.232275 | null | palbociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O | Launched | true | ACH-000905 |
BRD-K51791723-003-01-7 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | -0.00876 | 0.75436 | 0.427245 | 0.72858 | 0.890721 | 0.870449 | P276-00 | CDK inhibitor | CDK1, CDK4, CDK9 | null | null | CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000905 |
BRD-K51967704-001-03-6 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.194611 | 2.822506 | 0.610618 | 0.697047 | 0.259793 | 0.309378 | BIIB021 | HSP inhibitor | HSP90AA1 | null | null | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C | Phase 2 | true | ACH-000905 |
BRD-K52313696-001-12-3 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.714167 | 2.55611 | 0.162225 | 0.910824 | 0.484338 | null | tacedinaline | HDAC inhibitor | HDAC1 | null | null | CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N | Phase 3 | true | ACH-000905 |
BRD-K53414658-001-08-2 | ACH-000905 | 5637_URINARY_TRACT | MTS010 | 1 | 0.718402 | 0.923345 | 0.12596 | 0.869803 | 0.113516 | null | tivozanib | VEGFR inhibitor | FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB | null | null | COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC | Phase 3 | true | ACH-000905 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.